BACKGROUND: Human papillomavirus 68 (HPV68) is a probable carcinogenic HPV genotype which is included in almost all HPV screening assays and exists as two genetically variable subtypes (HPV68a and HPV68b). Routine HPV sample testing has shown that the cobas 4800 HPV Test (Roche) provides higher false-negative rates for HPV68 status than PapilloCheck HPV-Screening (Greiner Bio-One). The aim of our study was to evaluate the efficacy of cobas 4800 in HPV68 detection. METHODS: A total of 2,145 cervical/cervicovaginal samples from women aged 17-88 were tested for HPV68 status using the cobas 4800 and PapilloCheck HPV tests. Viral load was assessed by quantitative PCR in all of the HPV68-positive cases. HPV68a/b subtyping was performed with real-time PCR followed by high resolution melting curve analysis, and was subsequently confirmed by Sanger sequencing. RESULTS: Cobas 4800 detected HPV positivity in only 13/33 HPV68 single-genotype infection cases. Viral load was comparable across both tested subgroups. HRM analysis and Sanger sequencing identified the HPV68a subtype in all of the 20 instances of cobas 4800 false negatives. HPV68a and HPV68b were detected in 3/13 and 10/13 cases identified as other HPV-positive by cobas 4800. CONCLUSION: The HPV68a subtype was missed by cobas 4800 in more than 85% of all HPV68a-positive cases. Therefore, commercially available assays may underestimate HPV68 prevalence.

Cancer Research Czech Republic Olomouc Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6): 518–527. 10.1056/NEJMoa021641 PubMed DOI

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens- part B: biological agents. Lancet Oncol. 2009;10(4): 321–22. PubMed

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B): 1–441. Pubmed PMID: PMC4781184. PubMed PMC

Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4): 441–451. 10.1002/path.4405 PubMed DOI

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst. 2012;104(22): 1712–1723. 10.1093/jnci/djs395 PubMed DOI

Longuet M, Beaudenon S, Orth G. Two novel genital human papillomavirus (HPV) types, HPV68 and HPV70, related to the potentially oncogenic HPV39. J Clin Microbiol. 1996;34(3): 738–744. Pubmed PMID: PMC228882. PubMed PMC

Eklund C, Zhou T, Dillner J. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol. 2010;48(11): 4147–4155. 10.1128/JCM.00918-10, Pubmed PMID: PMC3020877. PubMed DOI PMC

Estrade C, Sahli R. Updating the PGMY primers and probes for improved detection of HPV68a: validation of version 2 of the PGMY-CHUV assay. J Clin Microbiol. 2014;52(11): 4033–4035. 10.1128/JCM.01950-14, Pubmed PMID: PMC4313245. PubMed DOI PMC

Eklund C, Forslund O, Wallin KL, Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. J Clin Microbiol. 2014;52(2): 449–459. 10.1128/JCM.02453-13, Pubmed PMID: PMC3911320. PubMed DOI PMC

Roche. Cobas®4800 HPV Test. Pleasanton, CA: Roche Molecular Systems, Inc; 2012. January 1.

Rao A, Young S, Erlich H, Boyle S, Krevolin M, Sun R, et al. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol. 2013;51(5): 1478–1484. 10.1128/JCM.03386-12, Pubmed PMID: PMC3647918. PubMed DOI PMC

Nadace pro Vyzkum Rakoviny. Let’s combat cancer together. Olomouc, Czech Republic: Nadace pro Vyzkum Rakoviny. Available at: http://www.vyzkumrakoviny.cz/lets-combat-cancer-together/ (accessed November 5, 2018)

Greiner Bio-One. PapilloCheck high-risk. Kremsmünster, Austria: Greiner Bio-One; 2012. November 20.

Jaworek H, Koudelakova V, Drabek J, Vrbkova J, Zborilova B, Oborna I, et al. A head-to-head analytical comparison of Cobas 4800 HPV, PapilloCheck HPV Screening, and LMNX Genotyping Kit HPV GP for detection of human papillomavirus dna in cervical and cervicovaginal swabs. J Mol Diagn. 2018;20(6): 849–858. 10.1016/j.jmoldx.2018.07.004 PubMed DOI

Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics 2007;23(10): 1289–1291. 10.1093/bioinformatics/btm091 PubMed DOI

Jaworek H, Koudelakova V, Slavkovsky R, Drabek J, Potockova J, Trojanec R, et al. The absence of high-risk human papillomavirus in Czech non-small cell lung cancer cases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019. 10.5507/bp.2018.079 PubMed DOI

Dwight ZL, Palais R, Kent J, Wittwer CT. Heterozygote PCR product melting curve prediction. Hum Mutat. 2014;35(3): 278–282. 10.1002/humu.22494 PubMed DOI

Kim NR, Kang M, Lee SP, Kim H, An J, Chung DH, et al. Uncommon and rare human papillomavirus genotypes relating to cervical carcinomas. Korean J Pathol. 2014;48(1): 43–49. 10.4132/KoreanJPathol.2014.48.1.43, Pubmed PMID: PMC3950234. PubMed DOI PMC

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11): 1048–1056. 10.1016/S1470-2045(10)70230-8 PubMed DOI

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26: K1–16. 10.1016/j.vaccine.2008.05.064 PubMed DOI

Batista JE, Saddi VA, Carvalho KPA, Ribeiro AA, Segati KD, Carneiro MADS, et al. Human papillomavirus genotypes 68 and 58 are the most prevalent genotypes in women from quilombo communities in the state of Maranhao, Brazil. Int J Infect Dis. 2017;55: 51–55. 10.1016/j.ijid.2017.01.001 PubMed DOI

Nascimento MDDS, Vidal FCB, Silva MACN, Batista JE, Lacerda Barbosa MDC, Muniz Filho WE, et al. Prevalence of human papillomavirus infection among women from quilombo communities in northeastern Brazil. BMC Womens Health. 2018;18(1): 1 10.1186/s12905-017-0499-3, Pubmed PMID: PMC5748955. PubMed DOI PMC

Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol. 2015;137(1): 47–54. 10.1016/j.ygyno.2015.01.551 PubMed DOI

Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10): 2349–2359. 10.1002/ijc.27485 PubMed DOI

Xu L, Ostrbenk A, Poljak M, Arbyn M. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework. J Clin Virol. 2018;98: 37–42. 10.1016/j.jcv.2017.12.001 PubMed DOI

Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005;97(2): 147–150. 10.1093/jnci/dji014 PubMed DOI